European Journal of Clinical Pharmacology

, Volume 23, Issue 2, pp 173–176

Pharmacokinetics of parenteral and oral melperone in man


  • L. Borgström
    • Department of BiochemistryResearch and Development Division, AB Ferrosan
  • H. Larsson
    • Department of BiochemistryResearch and Development Division, AB Ferrosan
  • L. Molander
    • Human Pharmacology LaboratoryResearch and Development Division, AB Ferrosan

DOI: 10.1007/BF00545974

Cite this article as:
Borgström, L., Larsson, H. & Molander, L. Eur J Clin Pharmacol (1982) 23: 173. doi:10.1007/BF00545974


The pharmacokinetics of melperone (Buronil®, Ferrosan, Sweden) was studied after administration of various parenteral and oral doses to man. After parenteral administration, the data could be fitted to a two-compartment model, but after oral dosing the distribution phase could not be separated from the elimination phase, and so an one-compartment model gave the best fit. The half-lives were about 3–4 h, except after intramuscular injection, when the half-life was about 6 h. The bioavailability of oral doses was about 60% of the intravenous injection. After the highest oral dose of 100 mg, the pharmacokinetics, expressed as AUC or Cmax, showed non-linearity, possibly due to saturation of the hepatic elimination system.

Key words

melperoneneuroleptic drugdose dependent kineticsi.m. injectioni.v. injectionpharmacokineticsoral application
Download to read the full article text

Copyright information

© Springer-Verlag 1982